Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN
(RTTNews) - Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
The Proclaim XR SCS system can provide relief to DPN patients in need of alternatives to traditional treatment approaches, such as oral medication. People who receive therapy from the Proclaim XR SCS system will also be able to use Abbott's NeuroSphere Virtual Clinic, a connected care app that allows people to communicate with a physician and receive treatment adjustments remotely.
Roughly 34.2 million Americans, or 10.5% of the U.S. population, have diabetes. Diabetic neuropathy, one of the complications of diabetes, is a type of damage seen predominately in nerves running to the feet.
Currently, there are no disease modifying treatments for DPN, only symptom management and behavioral modifications to mitigate further nerve damage that can result from high blood sugar (glucose) levels
Approved for the treatment of chronic pain in 2019, the Proclaim XR SCS system now offers DPN patients relief from chronic pain by delivering low amounts, or doses, of stimulation.
Abbott Q2 Profit Plunges, Lifts FY26 Adj. EPS View, Backs Sales Forecast; Stock Up 11%
Abbott Laboratories Boosts FY24 Earnings Outlook - Update
Abbott Says FDA Approves First-of-Its-Kind TriClip Transcatheter Edge-to-edge Repair System
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor
